Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Trelegy“
Suchtreffer
Begriffe & Kennungen
Trelegy Ellipta
Eintrag öffnenTrelegy Ellipta · 4.1 Therapeutic indications · 1
Eintrag öffnenTrelegy Ellipta · 4.3 Contraindications · 1
Eintrag öffnenTrelegy Ellipta · 4.3 · Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
Eintrag öffnenTrelegy Ellipta · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenTrelegy Ellipta · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenTrelegy Ellipta · 4.5 · 6 Other long acting antimuscarinics and long acting beta2- adrenergic agonists
Eintrag öffnenTrelegy Ellipta · 4.5 · Beta2-adrenergic blockers may weaken or antagonise the effect of beta2-adrenergic agonists, such as vilanterol
Eintrag öffnenTrelegy Ellipta · 4.5 · Caution is advised when co-administering with strong CYP3A4 inhibitors (e.g. ketoconazole, ritonavir, cobicist
Eintrag öffnenTrelegy Ellipta · 4.5 · Clinically significant drug interactions mediated by fluticasone furoate/umeclidinium/vilanterol at clinical d
Eintrag öffnenTrelegy Ellipta · 4.5 · Co-administration of Trelegy Ellipta with other long-acting muscarinic antagonists or long-acting beta2- adren
Eintrag öffnenTrelegy Ellipta · 4.5 · Concomitant hypokalaemic treatment with methylxanthine derivatives, steroids, or non-potassium-sparing diureti
Eintrag öffnenTrelegy Ellipta · 4.5 · Fluticasone furoate and vilanterol are rapidly cleared by extensive first pass metabolism mediated by enzyme C
Eintrag öffnenTrelegy Ellipta · 4.5 · Fluticasone furoate, umeclidinium and vilanterol are substrates of the P-glycoprotein transporter (P-gp). The
Eintrag öffnenTrelegy Ellipta · 4.5 · Hypokalaemia
Eintrag öffnenTrelegy Ellipta · 4.5 · Interaction with CYP2D6 inhibitors/CYP2D6 polymorphism
Eintrag öffnenTrelegy Ellipta · 4.5 · Interaction with CYP3A4 inhibitor
Eintrag öffnenTrelegy Ellipta · 4.5 · Interaction with P-glycoprotein inhibitors
Eintrag öffnenTrelegy Ellipta · 4.5 · Interaction with beta-blockers
Eintrag öffnenTrelegy Ellipta · 4.5 · Umeclidinium is a substrate of cytochrome P450 2D6 (CYP2D6). The steady-state pharmacokinetics of umeclidinium
Eintrag öffnen